Skip to Main Content
Contribute Try STAT+ Today

Sequencing company Illumina is planning to launch Galleri — the much-hyped cancer detection test from liquid biopsy company Grail, which it acquired in August — in Asian and African countries, according to the company’s CEO, Francis deSouza.

It’s a lofty goal with good intentions; deSouza said, speaking this week at the 2021 Milken Institute Global Conference, that the company hopes Illumina’s existing infrastructure will make the introduction of the $950 test far broader and far more rapid. But he declined to provide any other details about what rollouts in Asian and African markets might look like — or when they might start, or even offer more details.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment